Tuberculosis
Conditions
Keywords
Tuberculosis, Quantiferon Gold Plus test, Tuberculosis in children, SENEGAL, MTBVAC
Brief summary
A cross-sectional childhood M. tuberculosis infection survey of age-specific rates (defined by positivity to the test QuantiFERON-TB Gold Plus) will be conducted in Senegal to collect information on the local TB endemic to inform site selection, sample size, and recruitment strategies for a future efficacy trial of vaccine candidate MTBVAC in young children.
Detailed description
MTBVAC is a new TB vaccine candidate based on an attenuated clinical isolate of M. tuberculosis. The clinical development consortium of this EDCTP program is preparing for future years an MTBVAC efficacy trial by setting up a network of three African sites in South Africa, Senegal and Madagascar. Each site has established an operational clinical research infrastructure. As a first step, Senegal site needs to collect crucial epidemiological data on TB in children, to allow a rapid transition to a phase 3 trial in infants. The primary objective is to estimate the prevalence of TB infection by the QuantiFERON-TB Gold Plus technique in 500 children splined in 1-year, 2-year, 5-year, and 12-year-old age groups living in the study area (Saint Louis, Senegal). Secondary objectives are: * To study the socio-demographic characteristics, the vaccination history of each subject and the possible tuberculous contacts he has. * To map selected populations (from GPS residence data) according to the status (infected or uninfected) of each subject. * To ensure the orientation of children found positive by the QuantiFERON-TB Gold Plus test for care and follow-up related to the TB diagnosis and treatment at one of the Health Centers (THC) located in the study areas. * To estimate the number of tuberculosis cases detected in children aged up to 12 years and resident in the study area from THC registries and data from the National Tuberculosis Control Plan (PNB).
Interventions
DIAGNOSTIC_TESTQuantiferon Gold Plus Test
Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
Sponsors
Biofabri, S.L
TuBerculosis Vaccine Initiative
Universidad de Zaragoza
University of Cape Town
Institut Pasteur de Madagascar
Biomedical Research Center EPLS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
11 Months to 12 Years
Healthy volunteers
Yes
Inclusion criteria
* Children resident in the study area (St Louis City) * Obtaining written consent from one of the parents / guardians. * Children meeting one the following age criterion: * 1-year old child (12 months -1/+4 months); * 2-year-old child (24 months -1/+4 months); * 5-year old child (60 months +/-6 months); * 12-year old child (12 years old +/-6 months);
Exclusion criteria
* Child resident outside the study area. * Participation refusal by one of the parents / guardians. * Objection of the child belonging to the 12-year old group. * Child with a known chronic pathology (severe asthma, epilepsy, type 1 diabetes, severe immunosuppression ...) * Child considered by the Principal Investigator as medically unfit to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tuberculosis prevalence in children living in urban area in Senegal. | 2 days | To estimate the prevalence of TB infection by QuantiFERON-TB Gold Plus test in children aged 1 year, 2 years, 5 years and 12 years in the city of Saint Louis, Senegal. Blood samples are incubated with TB antigens and then Interferon Gamma production is evaluated by Elisa. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| health survey of the cohort | 2 hours | To carry out a standard questionnaire of the mother of the child included about his vaccinations, the conditions of the child's life and the tuberculous history of his relatives. |
Countries
France
Outcome results
None listed